Published in J Nucl Med on April 20, 2009
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging (2012) 6.36
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging (2013) 2.10
Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR (2010) 2.09
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med (2012) 1.62
PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging (2010) 1.60
Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. Eur J Nucl Med Mol Imaging (2010) 1.58
Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. Med Phys (2010) 1.49
18F-FDG PET-CT uptake is a feature of both normal diameter and aneurysmal aortic wall and is not related to aneurysm size. Eur J Nucl Med Mol Imaging (2014) 1.47
Variability in PET quantitation within a multicenter consortium. Med Phys (2010) 1.46
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44
Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging (2015) 1.43
Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging (2013) 1.40
PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error. Transl Oncol (2009) 1.38
Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging (2011) 1.28
Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging (2011) 1.23
Quantifying and reducing the effect of calibration error on variability of PET/CT standardized uptake value measurements. J Nucl Med (2011) 1.18
Risk stratification of solitary pulmonary nodules by means of PET using (18)F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging (2010) 1.17
Assessment of lung inflammation with 18F-FDG PET during acute lung injury. AJR Am J Roentgenol (2010) 1.17
Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol (2013) 1.10
Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. Eur Radiol (2012) 1.09
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology. Nucl Med Mol Imaging (2014) 1.08
The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Sci Rep (2015) 1.08
Liver SUV versus stage in Hodgkin's lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging (2014) 1.07
Current status of methods to assess cancer drug resistance. Int J Med Sci (2011) 1.07
Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A (2015) 1.06
FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol (2013) 1.02
Design considerations for using PET as a response measure in single site and multicenter clinical trials. Acad Radiol (2011) 1.02
Biases in Multicenter Longitudinal PET Standardized Uptake Value Measurements. Transl Oncol (2014) 1.02
Measurement of metabolic tumor volume: static versus dynamic FDG scans. EJNMMI Res (2011) 1.02
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging (2011) 1.01
The physical basis and future of radiation therapy. Br J Radiol (2011) 0.99
Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome? AJR Am J Roentgenol (2011) 0.97
Effects of surfactant depletion on regional pulmonary metabolic activity during mechanical ventilation. J Appl Physiol (1985) (2011) 0.97
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging (2014) 0.96
A review on segmentation of positron emission tomography images. Comput Biol Med (2014) 0.94
Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging (2013) 0.93
PET/CT without capacity limitations: a Danish experience from a European perspective. Eur Radiol (2011) 0.92
Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials. Magn Reson Imaging (2012) 0.91
Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns. Med Phys (2013) 0.91
Reproducibility of (18)F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Res (2016) 0.90
A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : The QUEST Phantom Study. Eur J Nucl Med Mol Imaging (2015) 0.90
The distribution of FDG at PET examinations constitutes a relative mechanism: significant effects at activity quantification in patients with a high muscular uptake. Eur J Nucl Med Mol Imaging (2012) 0.90
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging (2013) 0.90
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2014) 0.89
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front Med (Lausanne) (2015) 0.89
Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on (18)F-FDG PET-CT for radiotherapy treatment planning. Rep Pract Oncol Radiother (2012) 0.89
Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions. Nucl Med Mol Imaging (2013) 0.89
Repeatability of hypoxia PET imaging using [(18)F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. Eur J Nucl Med Mol Imaging (2015) 0.88
FDG-PET imaging in mild traumatic brain injury: a critical review. Front Neuroenergetics (2014) 0.88
How to assess intra- and inter-observer agreement with quantitative PET using variance component analysis: a proposal for standardisation. BMC Med Imaging (2016) 0.87
(18)F-FDG-PET/CT in the assessment of pulmonary solitary nodules: comparison of different analysis methods and risk variables in the prediction of malignancy. Transl Lung Cancer Res (2015) 0.87
The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer (2013) 0.86
Positron emission tomography-computed tomography in the management of lung cancer: An update. South Asian J Cancer (2013) 0.86
Effects of rigid and non-rigid image registration on test-retest variability of quantitative [18F]FDG PET/CT studies. EJNMMI Res (2012) 0.86
The applications of corrected standardized uptake values in the diagnosis of peripheral lung lesions. Medicine (Baltimore) (2015) 0.86
Accuracy of CT-based attenuation correction in PET/CT bone imaging. Phys Med Biol (2012) 0.85
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging (2013) 0.85
What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions? Eur J Nucl Med Mol Imaging (2014) 0.85
Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials. Clin Transl Imaging (2014) 0.85
Functional and molecular image guidance in radiotherapy treatment planning optimization. Semin Radiat Oncol (2011) 0.85
PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol (2015) 0.84
Feasibility of in situ, high-resolution correlation of tracer uptake with histopathology by quantitative autoradiography of biopsy specimens obtained under 18F-FDG PET/CT guidance. J Nucl Med (2015) 0.84
Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2012) 0.84
18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol (2013) 0.84
A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems. Mol Imaging Biol (2015) 0.83
Detection of murine post-pneumonectomy lung regeneration by 18FDG PET imaging. EJNMMI Res (2012) 0.83
Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiother Oncol (2014) 0.83
PET imaging in pediatric neuroradiology: current and future applications. Pediatr Radiol (2009) 0.82
Intra-individual comparison of PET/CT with different body weight-adapted FDG dosage regimens. Acta Radiol Open (2015) 0.82
Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer. Eur J Nucl Med Mol Imaging (2011) 0.82
Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging. Eur J Nucl Med Mol Imaging (2011) 0.81
FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements. Front Oncol (2011) 0.81
Variation in urinary excretion of FDG, yet another uncertainty in quantitative PET. Acta Radiol Short Rep (2012) 0.81
Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2016) 0.81
(18)F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. Eur J Nucl Med Mol Imaging (2016) 0.80
Multivariate analysis of various factors affecting background liver and mediastinal standardized uptake values. Indian J Nucl Med (2012) 0.80
Invalidity of SUV Measurements of Lesions in Close Proximity to Hot Sources due to "Shine-Through" Effect on FDG PET-CT Interpretation. Radiol Res Pract (2012) 0.80
(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2013) 0.80
Patient's weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients. Eur J Nucl Med Mol Imaging (2016) 0.80
A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics. Ann Biomed Eng (2013) 0.79
Multimodality molecular imaging of the lung. J Magn Reson Imaging (2010) 0.79
FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value. Cancers (Basel) (2015) 0.79
Positron emission tomography to assess hypoxia and perfusion in lung cancer. World J Clin Oncol (2014) 0.79
Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT. PLoS One (2013) 0.79
The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour. Eur Arch Otorhinolaryngol (2010) 0.79
Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer. J Nucl Med (2016) 0.79
EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging (2017) 0.79
Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers. World J Radiol (2014) 0.79
A method of adjusting SUV for injection-acquisition time differences in (18)F-FDG PET imaging. Eur Radiol (2011) 0.78
Calculating an estimate of tissue integrated activity in 18F-FDG PET imaging using one SUV value. EJNMMI Res (2013) 0.78
Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al. Neuro Oncol (2013) 0.78
Optimisation and harmonisation: two sides of the same coin? Eur J Nucl Med Mol Imaging (2013) 0.78
Comparison of SUVs Normalized by Lean Body Mass Determined by CT with Those Normalized by Lean Body Mass Estimated by Predictive Equations in Normal Tissues. Nucl Med Mol Imaging (2012) 0.78
Receiver operating characteristic (ROC) curve for classification of (18)F-NaF uptake on PET/CT. Radiol Bras (2016) 0.78